C15H22N2O2, orthorhombic, P212121a = 5.27590(10) Å, b = 10.3482(3) Å, c = 23.5372(6) Å, V = 1285.04(6) Å3, Z = 4, Rgt(F) = 0.0338, wRref(F2) = 0.0852, T = 100(1) K
C15H16N4O, monoclinic, P21/c (no. 14), a = 10.3021(8) Å, b = 15.7835(13) Å, c = 8.3052(7) Å, β = 90....
C6H9IN2O3, monoclinic, P21/c$P{2}_{1}/c$ (no. 14), a = 9.3654(2) Å, b = 8.0312(2) Å, c = 12.7668(3) ...
The title compound, C12H10N2O, a second monoclinic polymorph of (E)-phenyl(pyridin-2-yl)methanone ox...
C24H25NO3PRh, orthorhombic, P212121 (no. 19), a = 9.5498(1) Å, b = 13.4996(2) Å, c = 17.428(3) Å, V ...
C17H20O2, monoclinic, P121/n1 (no. 14), a = 6.618(1) Å, b = 27.538(5) Å, c = 14.951(3) Å, β = 98.768...
C60H64N18O30V10, orthorhombic, Pbca (no. 61), a = 21.1781(19) Å, b = 14.4198(13) Å, c = 24.543(2) Å,...
C15H16CeN7O10, monoclinic, P21/n (no. 14), a = 7.8762(12) Å, b = 21.330(3) Å, c = 13.181(2) Å, β = 9...
C12H9N2Br, triclinic, P1‾$\overline{1}$ (no. 2), a = 7.4005(13) Å, b = 9.4122(16) Å, c = 9.7916(17) ...
The crystal structure of the title compound has been determined by the symbolic addition method from...
The crystal structure of the title compound has been determined by the symbolic addition method from...
C7H4NO4Rh, monoclinic, P21/c (no. 14), a = 3.5780(12) Å, b = 10.932(4) Å, c = 20.866(7) Å, β = 94...
C14H10O2, triclinic, P1 (no. 2), a = 7.498(3) Å, b = 7.973(3) Å, c = 9.660(4) Å, α = 67.211(13)°, β ...
C10H17ClN2O10Sn, triclinic, P1 (no. 1), a = 6.6666(3) Å, b = 6.6892(4) Å, c = 8.8779(6) Å, α = 101.3...
C19H17N9O2, monoclinic, C2/c (no. 15), a = 20.297(7) Å, b = 10.122(3) Å, c = 9.078(3) Å, β = 95.675(...
C21H22N6O8S2, monoclinic, P12(1)/n1 (no. 14), a = 10.1931(8) angstrom, b = 11.9627(7) angstrom, c = ...
C15H16N4O, monoclinic, P21/c (no. 14), a = 10.3021(8) Å, b = 15.7835(13) Å, c = 8.3052(7) Å, β = 90....
C6H9IN2O3, monoclinic, P21/c$P{2}_{1}/c$ (no. 14), a = 9.3654(2) Å, b = 8.0312(2) Å, c = 12.7668(3) ...
The title compound, C12H10N2O, a second monoclinic polymorph of (E)-phenyl(pyridin-2-yl)methanone ox...
C24H25NO3PRh, orthorhombic, P212121 (no. 19), a = 9.5498(1) Å, b = 13.4996(2) Å, c = 17.428(3) Å, V ...
C17H20O2, monoclinic, P121/n1 (no. 14), a = 6.618(1) Å, b = 27.538(5) Å, c = 14.951(3) Å, β = 98.768...
C60H64N18O30V10, orthorhombic, Pbca (no. 61), a = 21.1781(19) Å, b = 14.4198(13) Å, c = 24.543(2) Å,...
C15H16CeN7O10, monoclinic, P21/n (no. 14), a = 7.8762(12) Å, b = 21.330(3) Å, c = 13.181(2) Å, β = 9...
C12H9N2Br, triclinic, P1‾$\overline{1}$ (no. 2), a = 7.4005(13) Å, b = 9.4122(16) Å, c = 9.7916(17) ...
The crystal structure of the title compound has been determined by the symbolic addition method from...
The crystal structure of the title compound has been determined by the symbolic addition method from...
C7H4NO4Rh, monoclinic, P21/c (no. 14), a = 3.5780(12) Å, b = 10.932(4) Å, c = 20.866(7) Å, β = 94...
C14H10O2, triclinic, P1 (no. 2), a = 7.498(3) Å, b = 7.973(3) Å, c = 9.660(4) Å, α = 67.211(13)°, β ...
C10H17ClN2O10Sn, triclinic, P1 (no. 1), a = 6.6666(3) Å, b = 6.6892(4) Å, c = 8.8779(6) Å, α = 101.3...
C19H17N9O2, monoclinic, C2/c (no. 15), a = 20.297(7) Å, b = 10.122(3) Å, c = 9.078(3) Å, β = 95.675(...
C21H22N6O8S2, monoclinic, P12(1)/n1 (no. 14), a = 10.1931(8) angstrom, b = 11.9627(7) angstrom, c = ...
C15H16N4O, monoclinic, P21/c (no. 14), a = 10.3021(8) Å, b = 15.7835(13) Å, c = 8.3052(7) Å, β = 90....
C6H9IN2O3, monoclinic, P21/c$P{2}_{1}/c$ (no. 14), a = 9.3654(2) Å, b = 8.0312(2) Å, c = 12.7668(3) ...
The title compound, C12H10N2O, a second monoclinic polymorph of (E)-phenyl(pyridin-2-yl)methanone ox...
DOI
Add to ORKG